FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205830177> ?p ?o ?g. }

• W4205830177 endingPage "03" @default.
• W4205830177 startingPage "PS14" @default.
• W4205830177 abstract "Abstract Background: While the incidence of breast cancer in men is up to 100-fold less than in women, it is estimated that in 2020, 2,620 men in the United States will be diagnosed with breast cancer, and 520 will die from this disease. However, male patients are rarely included in breast cancer clinical trials and treatment guidelines for this population are often proposed based on data from female patients. Ribociclib (RIB), an oral, selective cyclin-dependent kinase 4/6 inhibitor, is approved for use in combination with endocrine therapy (ET) in women with HR+, HER2- ABC. Here, we present a subgroup analysis of male patients from the Core Phase of CompLEEment-1 (NCT02941926), a Phase IIIb trial of RIB in combination with letrozole (LET) in patients with HR+, HER2- ABC. In order to reflect a more typical real-world clinical setting, the eligibility criteria for this study allowed for a more diverse and broader patient population than those of previous Phase III trials of RIB + LET. Methods: CompLEEment-1 included women of any menopausal status and men with HR+, HER2- ABC treated with ≤1 line of prior chemotherapy and no prior hormonal therapy for advanced disease. Pts received RIB (600 mg QD, 3 weeks on/1 week off) in combination with LET (2.5 mg QD, continuous). Men and premenopausal women received a luteinizing hormone-releasing hormone agonist (3.6 mg goserelin or 7.5 mg leuprolide, Q28D). This subgroup analysis assessed the primary outcomes (safety and tolerability) and secondary outcomes of time to progression (TTP), overall response rate (ORR), and clinical benefit rate (CBR) in male patients. Results: At the data cutoff date (November 8, 2019), 39 male patients (1.2%; N = 3,246) had been evaluated, with a median duration of exposure to RIB of 19.2 months. Adverse events (AEs) were reported in 38 (97.4%) patients; with all but two experiencing a treatment-related AE. Grade ≥ 3 AEs were reported in 26 (66.7%) patients; serious AEs were reported in 6 patients. There were no treatment-related fatal AEs. The most common all-grade AEs were neutropenia (53.8%), hot flush (33.3%), and diarrhea (25.6%), with the most common grade ≥ 3 AE being neutropenia (41.0%). Overall, 7 patients (17.9%) had ≥ 1 dose reduction of RIB, all of whom had at least 1 due to an AE, and 18 patients (46.2%) permanently discontinued treatment, 4 (10.3%) due to AEs. Median TTP was not estimable (95% CI, 16.8-NE); event-free probability was 61.4% (95% CI, 38.4-77.9) at 30 months. For the 32 patients with measurable disease, ORR was 46.9% (95% CI, 29.1-65.3%) and CBR was 71.9% (95% CI, 53.3-86.3). Conclusions: In this subgroup analysis of male patients - a rare population who are often excluded from clinical trials - efficacy results support the use of RIB + LET in HR+, HER2- ABC in a close to real-world setting. The safety profile associated with RIB + LET was manageable, with very few patients discontinuing treatment due to AEs, consistent with previous Phase III trials of RIB + LET. Citation Format: Mario Campone, Michelino De Laurentiis, Claudio Zamagni, Igor Kudryavcev, Mariëtte Agterof, Ursa Brown-Glaberman, Markéta Pálácova, Sanjoy Chatterjee, Lakshmi Menon-Singh, Jiwen Wu, Katie Zhou, Miguel Martín. Ribociclib + letrozole in male patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) advanced breast cancer (ABC): Subgroup analysis of the phase IIIb CompLEEment-1 trial [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS14-03." @default.
• W4205830177 created "2022-01-25" @default.
• W4205830177 creator A5001498807 @default.
• W4205830177 creator A5003606722 @default.
• W4205830177 creator A5018118709 @default.
• W4205830177 creator A5027231461 @default.
• W4205830177 creator A5037319969 @default.
• W4205830177 creator A5043850374 @default.
• W4205830177 creator A5052581732 @default.
• W4205830177 creator A5057850546 @default.
• W4205830177 creator A5068367016 @default.
• W4205830177 creator A5071553983 @default.
• W4205830177 creator A5081543974 @default.
• W4205830177 creator A5085420736 @default.
• W4205830177 date "2021-02-15" @default.
• W4205830177 modified "2023-10-18" @default.
• W4205830177 title "Abstract PS14-03: Ribociclib + letrozole in male patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2−) advanced breast cancer (ABC): Subgroup analysis of the phase IIIb CompLEEment-1 trial" @default.
• W4205830177 doi "https://doi.org/10.1158/1538-7445.sabcs20-ps14-03" @default.
• W4205830177 hasPublicationYear "2021" @default.
• W4205830177 type Work @default.
• W4205830177 citedByCount "0" @default.
• W4205830177 crossrefType "journal-article" @default.
• W4205830177 hasAuthorship W4205830177A5001498807 @default.
• W4205830177 hasAuthorship W4205830177A5003606722 @default.
• W4205830177 hasAuthorship W4205830177A5018118709 @default.
• W4205830177 hasAuthorship W4205830177A5027231461 @default.
• W4205830177 hasAuthorship W4205830177A5037319969 @default.
• W4205830177 hasAuthorship W4205830177A5043850374 @default.
• W4205830177 hasAuthorship W4205830177A5052581732 @default.
• W4205830177 hasAuthorship W4205830177A5057850546 @default.
• W4205830177 hasAuthorship W4205830177A5068367016 @default.
• W4205830177 hasAuthorship W4205830177A5071553983 @default.
• W4205830177 hasAuthorship W4205830177A5081543974 @default.
• W4205830177 hasAuthorship W4205830177A5085420736 @default.
• W4205830177 hasConcept C121608353 @default.
• W4205830177 hasConcept C126322002 @default.
• W4205830177 hasConcept C143998085 @default.
• W4205830177 hasConcept C197934379 @default.
• W4205830177 hasConcept C23589133 @default.
• W4205830177 hasConcept C2775930923 @default.
• W4205830177 hasConcept C2777176818 @default.
• W4205830177 hasConcept C2778043895 @default.
• W4205830177 hasConcept C2778375690 @default.
• W4205830177 hasConcept C2778812593 @default.
• W4205830177 hasConcept C2780482068 @default.
• W4205830177 hasConcept C2908647359 @default.
• W4205830177 hasConcept C29456083 @default.
• W4205830177 hasConcept C530470458 @default.
• W4205830177 hasConcept C71924100 @default.
• W4205830177 hasConcept C99454951 @default.
• W4205830177 hasConceptScore W4205830177C121608353 @default.
• W4205830177 hasConceptScore W4205830177C126322002 @default.
• W4205830177 hasConceptScore W4205830177C143998085 @default.
• W4205830177 hasConceptScore W4205830177C197934379 @default.
• W4205830177 hasConceptScore W4205830177C23589133 @default.
• W4205830177 hasConceptScore W4205830177C2775930923 @default.
• W4205830177 hasConceptScore W4205830177C2777176818 @default.
• W4205830177 hasConceptScore W4205830177C2778043895 @default.
• W4205830177 hasConceptScore W4205830177C2778375690 @default.
• W4205830177 hasConceptScore W4205830177C2778812593 @default.
• W4205830177 hasConceptScore W4205830177C2780482068 @default.
• W4205830177 hasConceptScore W4205830177C2908647359 @default.
• W4205830177 hasConceptScore W4205830177C29456083 @default.
• W4205830177 hasConceptScore W4205830177C530470458 @default.
• W4205830177 hasConceptScore W4205830177C71924100 @default.
• W4205830177 hasConceptScore W4205830177C99454951 @default.
• W4205830177 hasIssue "4_Supplement" @default.
• W4205830177 hasLocation W42058301771 @default.
• W4205830177 hasOpenAccess W4205830177 @default.
• W4205830177 hasPrimaryLocation W42058301771 @default.
• W4205830177 hasRelatedWork W2690569173 @default.
• W4205830177 hasRelatedWork W2751810360 @default.
• W4205830177 hasRelatedWork W2892008472 @default.
• W4205830177 hasRelatedWork W2962497808 @default.
• W4205830177 hasRelatedWork W3044815817 @default.
• W4205830177 hasRelatedWork W4221165630 @default.
• W4205830177 hasRelatedWork W4226356606 @default.
• W4205830177 hasRelatedWork W4282924254 @default.
• W4205830177 hasRelatedWork W4367835219 @default.
• W4205830177 hasRelatedWork W4378570500 @default.
• W4205830177 hasVolume "81" @default.
• W4205830177 isParatext "false" @default.
• W4205830177 isRetracted "false" @default.
• W4205830177 workType "article" @default.